Why is Q4 such a commercial critical time for life sciences?

“Q4 is where commercial discipline meets opportunity. Budgets are tight but some may remain unspent, teams are under pressure to demonstrate ROI for this year and set themselves up for success in Q1. But Q4 offers an opportunity. There’s plenty of time to extend the impact of 2025’s investment and bump that ROI a little further.”

What are the biggest mistakes you see brands make with their remaining Q4 budget?

“Treating Q4 as transactional and focusing on activity volume rather than strategic value. Leaving it too late and missing the opportunity to align Q4 spend with 2026 objectives or performance metrics.
Underestimating the value of 2025’s insights to inform 2026’s segmentation or messaging. Ignoring HCP fatigue and repeating the same channel tactics without analysing how preferences have shifted.”

What quick-win opportunities still exist for Q4?

“There’s still time for high-impact, low-barrier engagement.
• If you want strategic guidance, advisory boards can draw together clinical insight to address specific challenges.
• Repurpose this year’s assets into bite-sized, multimedia content to support your busy customers.
• Develop or refresh your digital toolkits or data-led customer segmentation to help support your field force.
• Boost engagement through short, consent-driven omnichannel campaigns.”

How can teams turn short-term year-end activity into long-term value in 2026?

“Don’t think about it as standalone activity.
• Capture engagement metrics, consent and feedback loops to inform 2026 targeting and messaging.
• Repurpose campaign and event assets into evergreen materials.
• Apply insights from advisory boards or surveys to refine next-year’s value propositions.”

What differentiates Uniphar Commercial?

“Uniphar blends strategic consultancy, engagement excellence, people strategy and supply chain strength to give clients a full-service lifecycle approach that aligns investment with measurable outcomes.”

Can you share a real example where Q4 activity led to success in the following year?

“A great example is a paediatric brand that had seen three years of decline. In Q4, Uniphar implemented a rapid optimisation plan: refocused KAM activity, built digital content and re-engaged specialist prescribers through a series of compliant educational meetings. Within 12 months, market share increased by 15%, exceeding contractual objectives by 120%.
That year-end intervention became the foundation for a multi-year growth plan, showing that insight-led, short-term activation delivers long-term impact.”

If you could give one piece of advice to brand leaders planning for 2026, what would it be?

“The market remains pressured but agility and data-driven decision-making can help your competitive advantage.
Create the building blocks for strategic success. Align brand planning to patient pathways and customer drivers. And most of all, ensure every engagement creates real-world insight that informs the next. Uniphar’s model is built for this, insight to strategy, strategy to activation and activation to measurable impact, helping pharma thrive in uncertainty and deliver sustained value across 2026 and beyond.”

Partner with Uniphar Commercial to transform year-end investment into long-term commercial value.